Drug Handling in kidney and liver disease 2005

Download Report

Transcript Drug Handling in kidney and liver disease 2005

Drug Handling in kidney
and liver disease
Dr. Geoff Isbister
Drug Action
• Drugs tend to be small lipid-soluble
molecules
• Drugs must get access to sites of action
• Drugs tend to bind to tissues, usually
protein molecules
• Drugs alter the actions of enzymes, ion
channels and receptors
Drug Action
• ENZYME: example Angiotensin
Converting enzyme inhibitors
A I ----X---------->A II
lowered A II -----> Reduced BP
• ION CHANNELS: example Local
Anesthetics
Block Na channels--->Anesthesia
• Receptor Binding
– Receptors are specialised binding sites - often
on cell surface- which have specificity for
certain substances (incl drugs). Drugs may
activate or block the receptor
– Activation of the receptor changes the activity of
the cell: eg adrenaline activates the beta 1
receptors in the heart and speeds up the heart
– Drugs have selectivity for receptors: eg
Histamine2 antagonists- reduce histamineinduced acid secretion and heal peptic ulcers
Pharmacokinetics
• The study of the action of the body on the
drugs
• Pharmacokinetics is the study of the time
course of concentrations of drug in the body
• The way the body handles drugs determines
the dose, route and frequency of
administration
• The handling of drugs by the body can be
split into absorption, distribution and
elimination
Pharmacokinetics
• Rate of absorption
determines the time
to the peak
concentration
• The extent of
absorption
determines the
height of the peak
concentration and
the AUC
30
25
20
15
10
5
0
0
1 5 9 13
Time after
dosing
Pharmacodynamics
• The response of the tissue to the active
free concentration of drug present at the
site of action
• May also be changed by disease
processes
Type of Disease
• Renal disease – the nature of the
disease doesn’t matter very much,
the main determinant is the decline in
GFR
Routes of elimination - Kidney
• Some drugs are water-soluble and are
eliminated directly by the kidney
– Molecules with MW below 20000 diffuse into glom
filtrate.
– examples: gentamicin, digoxin, atenolol
– involves no chemical change to the drug
– in most cases occurs by filtration (and depends on
the GFR)
– in a few cases (eg penicillin) some tubular secretion
contributes to elimination
• Highly lipid-soluble drugs are filtered into the
tubules and then rapidly re-absorbed
– High protein binding will reduce filtration
Practical issues - treating real
patients
• Assessing kidney function is
straightforward
– serum creatinine reflects GFR
– relationship between serum creatinine and
GFR changes with age
Effects of age on renal function
• There is a steady and proportional decline
in average GFR with increasing age
• However the serum creatinine remains
unchanged
• Why is this?
Effects of age on renal function
(constant serum creatinine of 0.10
mmol/l)
100
90
80
70
60
50
40
30
20
10
0
20
40
60
80
Multiple Dosing - renally excreted drug
Approx 5 half-lives to reach steady state
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
Elderly
0
12
24
36
48
60
72
84
96
Drug Types
• Water soluble - excreted unchanged (by
the kidney)
• Lipid soluble
- filtered but fully reabsorbed in the kidney
- metabolised to polar products (filtered without
reabsorption)
A number of drugs are handled
by tubular mechanisms
• Two mechanisms
– Active tubular secretion – important
• Acidic drugs – frusemide, methotrexate, penicillins, salicylate,
uric acid, probenecid
• Bases – amiloride, morphine, quinine
• Passive diffusion
– After filtration lipid-soluble drugs will be re-absorbed
passively.
– Will depend on degree of ionization at certain pH
levels
Practical Examples of dosing
in renal failure
Gentamicin
• Practice is changing - trend to once/daily
dosing
• The interval between doses may be >24
hours in the presence of renal failure and in
the elderly
• Toxicity relates to trough concentrations,
particularly with prolonged therapy
• Toxicity mainly affects the kidney and 8th
cranial nerve
Digoxin
• In the presence of renal impairment the
dose must be reduced
• The dose is given once daily
• Elderly people almost invariably have
some renal impairment, so they usually
require dose reduction - normally a halving
of dose compared with young people
Summary
• Reduced elimination of drugs from the
body in the elderly will lead to
accumulation and toxicity
• Disease and old age lead to reduced
renal elimination of water-soluble drugs
• Co-morbidity and concomitant drug
therapy
Hepatic Disease
• Metabolism by the Liver :
– role of metabolism
– types of metabolism
• Clearance
– hepatic clearance
• Liver disease
Type of Disease
• In liver disease the type of disease does
matter:
– Hepatitis – not much effect
– Biliary obstruction – not much effect (initially)
– Cirrhosis – has major effects on drug handling
Assessing Function
• Assessing liver function is hard - no single
test of how well the liver metabolises
drugs
– Drug metabolism most likely to be impaired
when the patient has cirrhosis, and has
evidence of coagulation disturbances and low
albumin
Biotransformation
• Majority produces metabolites that are :
– less active
– more polar and water soluble
• Minority :
– Pro-drugs that require metabolism to be
active
– active metabolites
– more toxic (mutagenic, teratogenic etc.)
Drugs with Active Metabolites
DRUG
ACTIVE METABOLITE
allopurinol
amitriptyline
codeine
diazepam
procainamide
prednisone
primidone
aspirin
oxypurinol
nortriptyline
morphine
oxazepam
N-acetyl PA
prednisolone
phenobarbitone
salicylate
Types of Metabolism
• Phase 1 Reactions
– usually convert the parent drug into a more
polar metabolite by introducing or unmasking
a functional group (-OH, -NH2, -SH).
Metabolite is usually inactive.
• Phase 2 Reactions - Conjugation
– an endogenous substrate (glucuronic acid,
sulfuric acid, acetic acid, or amino acid) is
attached to a functional group on the drug or
phase I metabolite.
Absorption
Phase I
Phase II
conjugate
Drug
Drug
Elimination
Metabolism
Drug metabolite
with modified
activity
Inactive
drug
metabolite
conjugate
conjugate
Drug
Lipophilic
Hydrophilic
Phase I Reactions
• Mixed Function Oxidase:
– P450 enzyme system
– induced and inhibited
– hydroxylation and demethylation
– family of isoenzymes
• Monoamine Oxidase : catecholamines
• Dehydrogenases :eg. Alcohol dehydrogenase
Phase I - P450 System
•
•
•
•
•
FRAGILE
High specificity
Low volume
Energy dependent
First affected by liver disease
Cytochrome P450 System
• Not a single entity
• Family of related isoenzymes (about 30)
• Important for drug interactions :
– Enzyme induction
– Enzyme inhibition
• Genetic polymorphism
Phase II Reactions
Conjugation
•
•
•
•
•
Glucuronidation
Sulfation
Acetylation
Glutathione
Glycine
Phase II Reactions
Conjugation
•
•
•
•
•
ROBUST
High volume
Low specificity
Not energy dependent
Less effected by liver disease
Paracetamol toxicity – failure of
Phase II
Conjugation pathway saturates
 oxidation by P450
cytochrome pathway
Formation of toxic
metabolite NAPQI
Initially detoxified by glutathione
Glutathione
depletion
NAPQI accumulates and
binds to tissue
macromolecules - cell death
Sites of Biotransformation
• Liver
•
•
•
•
Lung
Kidney
Large and small intestine
Placenta
Hepatic Clearance
Liver
Systemic circulation
0.2
fraction escaping
extraction (1-E)
1.0
0.8
fraction extracted and
metabolised (E)
Extraction Ratio
• High extraction ratio :
– Effectively removed by the liver
– Limited by hepatic blood flow
– High first pass metabolism
– Eg. Lignocaine, propranolol, diltiazem,
morphine
– Less effected by changes in intrinsic
clearance, such as induction and inhibition
Extraction Ratio
• High Extraction ratio
– Clearance approximates organ blood flow
• Low Extraction ratio
– Clearance proportional to free drug in the
blood and intrinsic clearance of the liver
Liver Disease
• Severe disease before major effects on
metabolism
• Liver Disease :
– Hepatocellular disease
– Decrease liver perfusion
• Type of metabolism :
– Phase I
– Phase II
Disease Factors
• Disease Type :
– Acute hepatitis – little effect
– Biliary Obstruction – little effect
– Chronic Active Hepatitis – major effects
– Cirrhosis – major effects
• Indicators :
– Established cirrhosis, varices, splenomegaly,
jaundice, increased prothrombin time.
Disease Factors
• Poor perfursion
• Cardiac failure : limits blood flow so effects
those with high extraction ratios
– Eg. Lignocaine
– Combination with ischaemic liver injury
• Other low perfusion states :
– Other causes of shock
Recent theories to account for
impaired metabolism in cirrhosis
•
•
•
•
Intact hepatocyte mass
Sick cell theory
Impaired drug uptake/shunting theory
Oxygen limitation theory
Type of Metabolism
• Phase I, mainly P450
– Affected first
• Phase II
– Severe disease before any effect
– Eg. Paracetamol poisoning.
Other considerations
• Renal function may be impaired in
moderate to severe liver disease
– Creatinine levels are not predictive
• Pro-drug metabolism impairment
– Eg ACE inhibitors
• Pharmaco-dynamic disturbances
– Tissues may be excessively sensitive to
even low concentrations of the drug – eg
morphone in the brain in the presence of
severe liver disease